卵巢癌是一种很难早期发现的癌症，一旦诊断出来，往往为时已晚。考虑到卵巢癌几乎对现有的所有免疫疗法都没有反应，而该研究发现，阻断IL-4能够改变卵巢肿瘤微环境，使这种难治性肿瘤变得更容易治疗，这对卵巢癌研究来说是一个重大突破。

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Experts say ovarian cancer causes more deaths than all other female reproduction system cancers and is difficult to diagnose ...

Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Ovarian Cancer.

A noninvasive method involving brief, localized pulses of magnetic fields could improve chemotherapy effectiveness and reduce ...

Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc.today announced that they successfully applied Sutro’ ...